Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889275 · ClinicalTrials.gov registry record · Phase 1
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03889275 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 39 participants.
The verdict
NCT03889275, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The reason for the study is to find out if MEDI5395 and durvalumab will work and be safe for the treatment of solid tumors.
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL MEDI5395
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-10-24 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03889275
The ClinicalTrials.gov registry entry for NCT03889275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT03889275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03889275 about?
NCT03889275 is a clinical study titled "A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors". The reason for the study is to find out if MEDI5395 and durvalumab will work and be safe for the treatment of solid tumors.
What is the current status of trial NCT03889275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2019-10-24. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT03889275?
The interventions under investigation include: Durvalumab (BIOLOGICAL), MEDI5395 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03889275?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.